A deep dive into specific issues and answers to commonly asked questions. This section is regularly updated.
This infosheet is meant to remind applicants of the additional eligibility rules that apply to Cluster 3 calls and to avoid typical mistakes regarding practitioners' participation.
Read moreOpen Access to peer-review scientific publications is one of the mandatory Open Science requirements under Horizon Europe.
Read moreThe article 22.5 eligibility requirements establish ownership and control restrictions designed to protect the strategic interests of the European Union. This infosheet provides a comprehensive overview of what you need to know as an applicant.
Read moreThe CA is a private, legally binding contract between all beneficiaries of a Horizon Europe project. It regulates the internal organisation, rights and obligations of the consortium as a whole and it's members individually.
Read moreTRL is a nine-step scale measuring technical maturity from concept to deployment, used in EU programs like Horizon Europe. It spans TRL 1–3 (lab), 4–6 (relevant environment), and 7–9 (operational), focusing on technical (not market) readiness.
Read moreWhat exactly is a cascade call? What can you expect from these calls?
Read moreAccess to tailor-made coaching, mentoring, expertise and training delivered by specialised providers and adapted to your innovation stage.
Read moreThis infosheet on international cooperation provides an overview of all types of countries for Horizon Europe participation and its eligibilty.
Read moreThis infosheet provides an overview of the timeline towards the next EU Framework Programme for research & innovation as well as an overview of position and discussion papers that have been published so far.
Read moreCertain calls for proposals require the submission of Ownership Control Declarations as mandatory annex to the application.
Read moreTestimonial
The Department of Economy, Science and Innovation of the Flemish government coordinates the Horizon 2020 Coordination and Support Action SAPHIRe, which started on 1 December 2018. The aim of the project is to secure the adoption of personalised medicine in all European regions, including sparsely populated and remote regions and regions with different innovation capacities.
The activities of SAPHIRe are complementary to the smart specialisation partnership on personalised medicine – S3P4PM, which is also coordinated by the Department of Economy, Science and Innovation.
